FrancophonIA/ELRC3.0 huggingface dataset:
English: o dry skin o hair loss o inflammation around the hair shaft o itching o rash o redness o skin irritation and bumps caused by shaving o skin irritation o stinging, tingling or burning feeling on the skin
Estonian: o nahakuivus o karvade kadu o karvanääpsu põletik o kihelus o lööve o punetus o raseerimisest tingitud nahaärritus ja muhud o nahaärritus o nõelav, torkiv või põletav tunne nahal
English: Non-clinical data reveal no special hazard for humans based on conventional studies of repeat dose toxicity, genotoxicity and carcinogenic potential, including one photocarcinogenicity study in mice.
Estonian: Tavapärased kroonilise toksilisuse, genotoksilisuse ja kartsinogeensuse mittekliinilised uuringud (sealhulgas üks fotokartsinogeensuse uuring hiirtel) ei ole näidanud kahjulikku toimet inimesele.
English: Improved
Estonian: Mõningane paranemine
English: It may sting or burn if you put this cream on cut or irritated skin.
Estonian: Raseeritud või ärritatud nahal võib kreem põhjustada ärritust või põletust.
English: How to store Vaniqa
Estonian: Kuidas Vaniqa kreemi säilitada
English: Phenoxyethanol;
Estonian: Fenoksüetanool
English: Rare (affects 1 to 10 users in 10,000)
Estonian: Aeg-ajalt (esineb 1 kuni 10 kasutajal 1000st)
English: Macrogol cetostearyl ether;
Estonian: Makrogooltsetostearüüleeter Dimetikoon
English: Eflornithine
Estonian: Makrogoolstearaat
English: even if their symptoms are the same as yours.
Estonian: Ravim võib olla neile kahjulik, isegi kui haigusnähud on sarnased.
English: Uncommon (affects 1 to 10 users in 1,000)
Estonian: Harv (esineb 1 kuni 10 kasutajal 10 000st)
English: These improvements resulted in a corresponding reduction in the darkening appearance of the facial skin associated with the presence of terminal hair.
Estonian: Ravi tulemusena vähenes ka karvaotstest tingitud näonaha tumenemine.
English: Vaniqa 11.5% cream Vehicle
Estonian: Vaniqa 11,5% kreem Kreemialus
English: Use should be discontinued if no beneficial effects are noticed within four months of commencing therapy.
Estonian: Kui nelja ravinädala jooksul paranemismärke ei täheldata, tuleb kreemi kasutamine lõpetada.
English: If it persists contact your doctor.
Estonian: Ärrituse püsimisel pöörduge arsti poole.
English: Dimeticone;
Estonian: Kutaanne.
English: INSTRUCTIONS ON USE
Estonian: MANUSTAMISVIIS
English: Of those with no acne at baseline, similar percentages (14%) reported acne following treatment with Vaniqa or vehicle.
Estonian: Uuringu alguses aknet mittepõdenud patsientide seas oli ravi järel tekkinud aknega patsiente nii Vaniqa kui ka kreemialuse kasutajate seas 14%.
English: Stearyl alcohol;
Estonian: Stearüülalkohol
English: This is called ‘myeloablation'.
Estonian: Seda nimetatakse müeloablatsiooniks.
English: The European Commission granted a marketing authorisation valid throughout the EU for Busilvex on 9 July 2003.
Estonian: Euroopa Komisjon andis Busilvexi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 9. juulil
English: The full EPAR for Busilvex can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Busilvexi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: There were two main studies involving 103 adults and one involving 55 children.
Estonian: Korraldati kaks kliinilist põhiuuringut, milles osales kokku 103 täiskasvanut, ning üks uuring, milles osales 55 last.
English: Busilvex can affect fertility in both sexes.
Estonian: Busilvex võib mõjutada mõlema sugupoole viljakust.
English: Busilvex busulfan
Estonian: Busilvex busulfaan
English: Each infusion lasts for two hours and it is given to the patient every six hours on four consecutive days before treatment with cyclophosphamide or melphalan and the transplant.
Estonian: Iga infusioon kestab kaks tundi ning seda korratakse neljal järjestikusel päeval iga kuue tunni tagant enne ravi tsüklofosfamiidi või melfalaaniga ja siirdamist.
English: The Committee decided that Busilvex's benefits are greater than its risks in these settings and recommended that Busilvex be given marketing authorisation.
Estonian: Komitee otsustas, et Busilvexi kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
English: When used in combination with fludarabine, the recommended dose of Busilvex is 3.2 mg per kilogram given once a day as a three-hour infusion immediately after fludarabine, for 2 or 3 consecutive days.
Estonian: Kui ravimit kasutatakse koos fludarabiiniga, on Busilvexi soovitatav annus on 3,2 mg/kg kehakaalu kohta, mis manustatakse üks kord ööpäevas kolm tund kestva infusioonina vahetult pärast fludarabiini manustamist, 2 või 3 järjestikusel päeval.
English: Since Busilvex in combination with fludarabine has been used in clinical practice for many years, data from 7 studies (involving 731 patients) which looked at the effectiveness of Busilvex and fludarabine as ‘reduced-intensity' conditioning treatment were presented.
Estonian: Et kliinilises praktikas on kasutatud Busilvexi koos fludarabiiniga palju aastaid, esitati 7 uuringu (731 patsiendi) andmed, milles vaadeldi Busilvexi ja fludarabiini efektiivsust väiksema intensiivsusega ettevalmistava ravirežiimi korral.
English: For more information about treatment with Busilvex, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Busilvexiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Other information about Busilvex
Estonian: Muu teave Busilvexi kohta
English: The data from the published studies showed that Busilvex in combination with fludarabine was effective as a ‘reduced-intensity' conditioning treatment, with complete engraftment achieved in 80 to 100% of patients.
Estonian: Avaldatud uuringute andmed näitasid, et Busilvex koos fludarabiiniga oli vähendatud intensiivsusega ettevalmistava ravi korral efektiivne: siiratud rakud hakkasid talitlema 80-100%-l patsientidest.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Busilvex.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Because of this, female patients should not become pregnant during treatment and for up to six months afterwards, and male patients are advised not to father a child during and for up to six months after treatment with Busilvex.
Estonian: Naispatsiendid ei tohi ravi ajal ja kuni kuue kuu vältel pärast ravi rasestuda ning meespatsientidel on soovitatav vältida viljastamist ravi ajal ja kuni kuue kuu vältel pärast ravi.
English: This is a summary of the European public assessment report (EPAR) for Busilvex.
Estonian: See on ravimi Busilvex Euroopa avaliku hindamisaruande kokkuvõte.
English: Busilvex must not be used in women who are pregnant.
Estonian: Busilvexi ei tohi kasutada rasedatel.
English: Apart from the decrease in blood cell counts, which is the intended effect of the medicine, the most serious side effects of Busilvex are infection, liver disorders including blocking of a liver vein, graft versus host disease (when the transplanted cells attack the body) and respiratory (lung) disorders.
Estonian: Lisaks vererakkude sisalduse vähenemisele, mis on ravimi kasutamise eesmärk, on Busilvexi kõige raskemad kõrvalnähud infektsioonid (nakkused), maksahaigused, sh maksaveeni tromboos (sulgumine), siirikuhülgtõbi (siiratud rakud ründavad organismi) ja hingamiselundite (kopsude) haigused.
English: This helps the transplanted cells to ‘engraft' (when they start to grow and produce normal blood cells).
Estonian: See aitab siiratud rakkudel hakata organismis normaalselt talitlema (kasvama ja tootma normaalseid vererakke).
English: What is Busilvex?
Estonian: Mis on Busilvex?
English: The CHMP concluded that the effectiveness of Busilvex in combination with cyclophosphamide and melphalan for conventional conditioning, and with fludarabine for reduced-intensity conditioning had been shown; Busilvex also provides an alternative to busulfan tablets, which have disadvantages such as the large number of tablets that need to be taken.
Estonian: Inimravimite komitee järeldas, et Busilvexi efektiivsus koos tsüklofosfamiidi ja melfalaaniga tavapärase ettevalmistava ravimina ja fludarabiiniga väiksema intensiivsusega ettevalmistava ravirežiimi korral on tõendatud; Busilvex on ka alternatiiviks busulfaani tablettidele, millel on puudusi, näiteks manustatavate tablettide suur arv.
English: The main measures of effectiveness were the number of patients with myeloablation and ‘engraftment' (the time for the transplanted stem cells to begin growing and for white blood cells to return to higher levels).
Estonian: Efektiivsuse põhinäitaja oli patsientide arv, kellel toimus müeloablatsioon, ning siiratud rakkude talitlema hakkamise aeg (vere valgeliblede arvu suurenemiseni kulunud aeg).
English: What is the risk associated with Busilvex?
Estonian: Mis riskid Busilvexiga kaasnevad?
English: Cyclophosphamide, melphalan or fludarabine are used to suppress the immune system, so that the body's natural defences are decreased.
Estonian: Seejärel kasutatakse tsüklofosfamiidi või melfalaani, et pärssida immuunsüsteemi, vähendades organismi loodusliku kaitsemehhanismi toimet.
English: In adult patients who are eligible for a ‘reduced-intensity' conditioning regimen, Busilvex is given right after treatment with another medicine, fludarabine.
Estonian: Täiskasvanud patsientidele, kellel on vaja väiksema intensiivsusega ettevalmistavat ravirežiimi, manustatakse Busilvexi vahetult pärast ravi teise ravimi fludarabiiniga.
English: Busilvex is a concentrate to be made up into a solution for infusion (drip into a vein).
Estonian: Busilvex on kontsentraat, millest valmistatakse infusioonilahus (veeni tilgutatav lahus).
English: When Busilvex was given in combination with cyclophosphamide or melphalan, all adults and children achieved myeloablation.
Estonian: Kui Busilvexi manustati koos tsüklofosfamiidi või melfalaaniga, saavutati müeloablatsioon kõigil täiskasvanuil ja lastel.
English: For the full list of all side effects and restrictions with Busilvex, see the package leaflet.
Estonian: Busilvexi kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Why has Busilvex been approved?
Estonian: Miks Busilvex heaks kiideti?
English: It contains the active substance busulfan.
Estonian: Ravim sisaldab toimeainena busulfaani.
English: Busilvex in combination with cyclophosphamide or melphalan has been studied in patients, mainly with blood cancer, who needed transplantation of haematopoietic progenitor cells.
Estonian: Busilvexi ja tsüklofosfamiidi või melfalaani koostoimet uuriti vereloome eellassrakkude siirdamist vajavatel peamiselt verevähiga patsientidel.
English: When used in combination with cyclophosphamide or melphalan the recommended dose of Busilvex in adults is 0.8 mg per kilogram body weight.
Estonian: Koos tsüklofosfamiidi või melfalaaniga kasutamisel on Busilvexi soovitatav annus täiskasvanutel 0,8 mg kehakaalu kg kohta.
English: This means that they kill cells, especially cells that develop rapidly, such as cancer or progenitor (or ‘stem') cells (cells that make other types of cell).
Estonian: Need ained on tsütotoksilised: nad hävitavad rakke, eelkõige neid, mis arenevad kiiresti, nagu pahaloomulise kasvaja rakud või eellasrakud (tüvirakud, millest tekivad teist tüüpi rakud).
English: Busilvex should be used by a doctor who has experience in treatments given before transplantation.
Estonian: Busilvexi tohib kasutada üksnes siirdamiseelses ravis kogenud arst.
English: Busulfan is used before transplantation to destroy abnormal cells and the patient's existing haematopoietic progenitor cells.
Estonian: Busulfaani kasutatakse enne siirdamist ebanormaalsete rakkude ja patsiendi olemasolevate vereloome eellasrakkude hävitamiseks.
English: Busilvex is used in adults and children as part of a ‘conditioning' (preparative) treatment before transplantation of haematopoietic progenitor cells (the cells that make blood cells).
Estonian: Busilvexi kasutatakse täiskasvanutel ja lastel ettevalmistava ravimina enne vereloome eellasrakkude (rakud, millest tekivad vererakud) siirdamist.
English: The active substance in Busilvex, busulfan, belongs to a group of medicines called ‘alkylating agents'.
Estonian: Busilvexi toimeaine busulfaan kuulub alküülivate ainete ravimirühma.
English: For a conventional conditioning treatment, Busilvex is given before treatment with a second medicine, cyclophosphamide, in adults, and either cyclophosphamide or an alternative medicine, melphalan, in children.
Estonian: Tavapärasel kasutamisel manustatakse Busilvexi täiskasvanutele enne ravi teise ravimi tsüklofosfamiidiga ja lastele enne ravi kas tsüklofosfamiidi või melfalaaniga.
English: What is Busilvex used for?
Estonian: Milleks Busilvexi kasutatakse?
English: Breast-feeding should be stopped when treatment with Busilvex is started.
Estonian: Kui alustatakse ravi Busilvexiga, tuleb lapse imetamine lõpetada.
English: Engraftment was obtained in 13 days in adults and 21 days in children with ‘allotransplantation' (when the patient receives cells from a donor).
Estonian: Allotransplantatsioonil (kui patsiendile siiratakse doonorilt saadud rakke) saavutati siiratud rakkude talitlema hakkamine täiskasvanutel 13 päevaga ja lastel 21 päevaga.
English: What benefit has Busilvex shown during the studies?
Estonian: Milles seisneb uuringute põhjal Busilvexi kasulikkus?
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom of Busilvex varies between 0.8 and 1.2 mg per kilogram depending on the weight of the child. Busilvex is given as a central intravenous infusion (drip into a central vein in the chest).
Estonian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
English: How does Busilvex work?
Estonian: Kuidas Busilvex toimib?
English: On average, engraftment was reached in 10 days in adults and 11 days in children with ‘autotransplantation' (when the patient receives their own cells, harvested and stored before the transplant).
Estonian: Autotransplantatsioonil (kui patsiendile siiratakse tema enda rakke, mida võeti enne ravi ja säilitati) saavutati siiratud rakkude talitlema hakkamine täiskasvanutel keskmiselt 10 päevaga ja lastel 11 päevaga.
English: This type of transplant is used in patients who need to replace their blood-making cells, because they have a blood disorder (such as a rare type of anaemia) or a cancer of the blood.
Estonian: Vereloome eellasrakkude siirdamist kasutatakse mõne verehaigusega (näiteks aneemia teatud haruldase vormiga) või verevähiga patsientidel, kellel on seetõttu vaja vererakke tootvad rakud asendada.
English: Before receiving Busilvex, patients are given anticonvulsive medicines (to prevent seizures) and anti-emetic medicines (to prevent vomiting).
Estonian: Enne Busilvexi manustamist antakse patsientidele krambivastaseid ja oksendamisvastaseid ravimeid.
English: How is Busilvex used?
Estonian: Kuidas Busilvexi kasutatakse?
English: How has Busilvex been studied?
Estonian: Kuidas Busilvexi uuriti?
English: What measures are being taken to ensure the safe and effective use of Pifeltro?
Estonian: Mis meetmed võetakse, et tagada Pifeltro ohutu ja efektiivne kasutamine?
English: Pifeltro (doravirine)
Estonian: Pifeltro (doraviriin)
English: Further information on Pifeltro can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/pifeltro.
Estonian: Lisateave Pifeltro kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/pifeltro.
English: Pifeltro must not be used with certain medicines that may reduce its effectiveness.
Estonian: Pifeltrot ei tohi kasutada koos teatud ravimitega, sest need võivad vähendada selle efektiivsust.
English: The European Medicines Agency therefore decided that Pifeltro's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Pifeltro kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: In addition, Pifeltro's side effects are mostly mild.
Estonian: Peale selle on Pifeltro kõrvalnähud enamasti kerged.
English: Other information about Pifeltro
Estonian: Muu teave Pifeltro kohta
English: What is Pifeltro and what is it used for?
Estonian: Mis on Pifeltro ja milleks seda kasutatakse?
English: As for all medicines, data on the use of Pifeltro are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Pifeltro kasutamise kohta pidevat järelevalvet.
English: Pifeltro (doravirine) EMA/821744/2018
Estonian: Pifeltro (doraviriin) EMA/661893/2018
English: Side effects reported with Pifeltro are carefully evaluated and any necessary action taken to protect patients.
Estonian: Pifeltro kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: For more information about using Pifeltro, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Pifeltro kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: The most common side effects with Pifeltro (which may affect up to 1 in 10 people) are nausea (feeling sick) and headache.
Estonian: Pifeltro kõige sagedamad kõrvalnähud (võivad esineda kuni 1 patsiendil 10st) on iiveldus ja peavalu.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pifeltro have been included in the summary of product characteristics and the package leaflet.
Estonian: Pifeltro ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: What are the risks associated with Pifeltro?
Estonian: Mis riskid Pifeltroga kaasnevad?
English: Pifeltro is used together with other antiviral medicines.
Estonian: Pifeltrot kasutatakse koos muude viirusravimitega.
English: It does not cure HIV infection or AIDS but, when used in combination with other antivirals, it holds off the damage to the immune system and the development of infections and diseases associated with AIDS.
Estonian: See ei ravi HIV-nakkust ega AIDS-i välja, kuid võib immuunsüsteemi kahjustumist ning AIDS-iga seotud nakkuste ja haiguste tekkimist edasi lükata.
English: Pifeltro helps keep the amount of HIV in the blood at a low level.
Estonian: Pifeltro hoiab HIV-sisalduse veres väikese.
English: Pifeltro is an antiviral medicine used to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Estonian: Pifeltro on viirusravim, mida kasutatakse omandatud immuunpuudulikkuse sündroomi (AIDS) põhjustava inimese 1. tüüpi immuunpuudulikkuse viirusega (HIV-1) nakatunud täiskasvanute raviks.
English: How does Pifeltro work?
Estonian: Kuidas Pifeltro toimib?
English: Pifeltro is available as tablets (100 mg) and can only be obtained with a prescription.
Estonian: Pifeltro on retseptiravim ja seda turustatakse tablettidena (100 mg).
English: For the full list of side effects and restrictions with Pifeltro, see the package leaflet.
Estonian: Pifeltro kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: How is Pifeltro used?
Estonian: Kuidas Pifeltrot kasutatakse?
English: In a second study with 728 patients, 84% of patients treated with Pifeltro in combination with tenofovir disoproxil and lamivudine had undetectable HIV levels by 48 weeks compared with 80% of patients given a combination of efavirenz, tenofovir disoproxil and emtricitabine.
Estonian: Teises, 728 patsiendi uuringus, oli Pifeltrot koos tenofoviirdisoproksiili ja lamivudiiniga kasutanud patsientide seas patsiente, kellel ei tuvastatud 48 ravinädala järel veres HIVi, 84% ning efavirensi, tenofoviirdisoproksiili ja emtritsitabiini kombinatsiooni kasutanute seas 80%.
English: The medicine is not suitable for patients who are infected with HIV that is resistant to medicines in the same class as Pifeltro (non-nucleoside reverse transcriptase inhibitors or NNRTIs).
Estonian: See ei sobi patsientidele, kes on nakatunud HI-viirusega, mis on resistentne Pifeltroga samasse klassi kuuluvate ravimite (mittenukleosiidsete pöördtranskriptaasiinhibiitorite ehk NNRTIde) suhtes.
English: Studies showed that Pifeltro taken with other antivirals was as effective at keeping HIV infection under control as standard HIV combination treatments.
Estonian: Uuringud tõendasid, et koos muude viirusravimitega kasutatav Pifeltro oli HIV-nakkuse kontrolli all hoidmisel sama efektiivne kui standardne HIV-kombinatsioonravi.
English: Pifeltro used in combination with other antivirals is as effective as standard HIV combination treatments at keeping HIV infection under control.
Estonian: Koos teiste viirusravimitega kasutatav Pifeltro on HIV-nakkuse kontrolli alla hoidmisel sama efektiivne kui standardne HIV-kombinatsioonravi.
English: An overview of Pifeltro and why it is authorised in the EU
Estonian: Ülevaade ravimist Pifeltro ja ELis müügiloa väljastamise põhjendus
English: Pifeltro contains the active substance doravirine.
Estonian: Ravim sisaldab toimeainena doraviriini.
English: In a study of 766 patients, 83% of patients taking Pifeltro (together with either emtricitabine and tenofovir disoproxil or abacavir and lamivudine) had undetectable levels of HIV in their blood (fewer than 40 copies/ml) after 48 weeks of treatment.
Estonian: 766 patsiendi uuringus oli Pifeltrot (koos emtritsitabiini ja tenofoviirdisoproksiili või abakaviiri ja lamivudiiniga) kasutanud patsientide seas patsiente, kellel ei tuvastatud 48 ravinädala järel veres HIVi (viiruskoormus alla 40 koopia/ml), 83%.
English: What benefits of Pifeltro have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Pifeltro kasulikkus?
English: The active substance in Pifeltro, doravirine, is a non-nucleoside reverse transcriptase inhibitor (NNRTI).
Estonian: Pifeltro toimeaine doraviriin on mittenukleosiidne pöördtranskriptaasi inhibiitor (NNRTI), mis blokeerib pöördtranskriptaasi toime.
English: Doravirine blocks the activity of reverse transcriptase, an enzyme that allows HIV to reproduce itself in the cells it has infected.
Estonian: Pöördtranskriptaas on ensüüm, mis võimaldab HI-viirusel nakatunud rakkudes paljuneda.
English: This compares with 79% of patients taking standard combination of darunavir plus ritonavir (together with either emtricitabine and tenofovir disoproxil or abacavir and lamivudine).
Estonian: Darunaviiri ja ritonaviiri standardkombinatsiooni kasutanutest (koos emtritsitabiini ja tenofoviirdisoproksiili või abakaviiri ja lamivudiiniga) oli selliseid patsiente 79%.
English: Why is Pifeltro authorised in the EU?
Estonian: Pifeltro Euroopa Liidus heakskiitmise põhjused
English: 1ml (200 mg/ml) 12 (3 x 4) pre-filled pens (multipack)
Estonian: 12 (3 x 4) pen-süstlit (mitmikpakend)
English: Immediate Packaging
Estonian: 4 süstlit
English: 1ml (200 mg/ml) 4 pre-filled syringes
Estonian: 4 pen-süstlit
English: What measures are being taken to ensure the safe and effective use of Avastin?
Estonian: Mis meetmed võetakse, et tagada Avastini ohutu ja efektiivne kasutamine?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Avastin on 12 January 2005.
Estonian: Euroopa Komisjon andis Avastini müügiloa, mis kehtib kogu Euroopa Liidus, 12. jaanuaril 2005.
English: The full EPAR for Avastin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Avastini kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.